Previous close | 36.20 |
Open | 42.00 |
Bid | 41.30 |
Ask | 46.00 |
Strike | 70.00 |
Expiry date | 2024-01-19 |
Day's range | 42.00 - 42.00 |
Contract range | N/A |
Volume | |
Open interest | 69 |
Bagsværd, Denmark, 2 February 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their
Merck (MRK) beats Q4 estimates for earnings and sales. Its 2023 profit guidance disappoints. Stock declines in pre-market.
My name is Lars Fruergaard Jorgensen, and I'm the CEO of Novo Nordisk. With me today, I have executive vice president and head of commercial strategy and corporate affairs, Camilla Sylvest; executive vice president and head of North America operations, Doug Langa; executive vice president and head of development, Martin Holst Lange; and finally, chief financial officer, Karsten Munk Knudsen.